ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,071.63
      0.02%
      US Tech 100
      17,060.40
      0.00%
      Dow Jones
      38,460.92
      -0.11%
      Brent Oil
      87.48
      0.30%
      Bitcoin
      64,001.59
      -0.43%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Affimed NV (AFMD)

      7. Affimed NV (AFMD) News

      AFMD

      Affimed NV (AFMD)

      Affimed NV
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:AFMD
      DateTimeSourceHeadlineSymbolCompany
      04/24/20244:05AMGlobeNewswire Inc.Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyNASDAQ:AFMDAffimed NV
      03/28/20246:30AMGlobeNewswire Inc.Affimed Reports 2023 Financial Results and Operational ProgressNASDAQ:AFMDAffimed NV
      03/21/20246:30AMGlobeNewswire Inc.Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024NASDAQ:AFMDAffimed NV
      03/11/20244:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      03/06/20246:34AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      03/06/20246:30AMGlobeNewswire Inc.Affimed Announces 1-for-10 Reverse Stock SplitNASDAQ:AFMDAffimed NV
      01/08/20244:45PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      01/08/20244:05PMGlobeNewswire Inc.Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerNASDAQ:AFMDAffimed NV
      01/08/20248:11AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      01/08/20248:00AMGlobeNewswire Inc.Affimed Announces Leadership Change and Organizational RestructuringNASDAQ:AFMDAffimed NV
      01/03/20246:30AMGlobeNewswire Inc.Affimed Announces Sale of Wholly-Owned Subsidiary AbCheckNASDAQ:AFMDAffimed NV
      12/11/20236:10AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      12/11/20236:02AMGlobeNewswire Inc.Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer PatientsNASDAQ:AFMDAffimed NV
      12/11/20236:00AMGlobeNewswire Inc.Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)NASDAQ:AFMDAffimed NV
      12/04/20236:30AMGlobeNewswire Inc.Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24NASDAQ:AFMDAffimed NV
      11/30/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      11/14/20236:30AMGlobeNewswire Inc.Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressNASDAQ:AFMDAffimed NV
      11/09/20236:30AMGlobeNewswire Inc.Affimed Announces Acimtamig as International Nonproprietary Name for AFM13NASDAQ:AFMDAffimed NV
      11/07/20236:30AMGlobeNewswire Inc.Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023NASDAQ:AFMDAffimed NV
      11/03/202312:05PMGlobeNewswire Inc.Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of CancerNASDAQ:AFMDAffimed NV
      11/02/20239:05AMGlobeNewswire Inc.Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual MeetingNASDAQ:AFMDAffimed NV
      11/01/20236:30AMGlobeNewswire Inc.Affimed to Participate in Upcoming Investor ConferencesNASDAQ:AFMDAffimed NV
      10/04/20236:40AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      10/04/20236:30AMGlobeNewswire Inc.Affimed Announces Listing Transfer to Nasdaq Capital MarketsNASDAQ:AFMDAffimed NV
      09/27/20239:05AMGlobeNewswire Inc.Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of CancerNASDAQ:AFMDAffimed NV
      09/21/20236:30AMGlobeNewswire Inc.Affimed to Present at the Cantor Global Healthcare Conference 2023NASDAQ:AFMDAffimed NV
      09/12/20236:30AMGlobeNewswire Inc.Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin LymphomaNASDAQ:AFMDAffimed NV
      09/07/20236:30AMGlobeNewswire Inc.Affimed to Present at the H.C. Wainwright Annual Global Investment ConferenceNASDAQ:AFMDAffimed NV
      08/22/20235:00AMGlobeNewswire Inc.Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal DevelopabilityNASDAQ:AFMDAffimed NV
      08/10/20236:45AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
       Showing the most relevant articles for your search:NASDAQ:AFMD